ROKIT Healthcare
Founded 2012 · 70 employees on LinkedIn · 9 known investors
Healthcare company that recently went public.
Also known as Rokit Healthcare · ROKIT HEALTHCARE
Investors · 9
Also in the syndicate · 8
Company profile
researched Aug 2026ROKIT Healthcare is a South Korean regenerative medicine and biotechnology company that develops an "Organ Regeneration Platform" combining 3D bioprinting with autologous (patient-derived) cells and tissue to regenerate and restore the function of human tissues and organs. Its clinical focus areas are diabetic foot ulcers, chronic kidney disease and degenerative arthritis — chronic conditions the company characterizes as requiring long-term management and carrying risks such as infection, amputation, dialysis or transplantation.
The platform has three stated components: precision bioprinting, in which 3D bioprinters produce custom tissue grafts intended to integrate with a patient's own tissue; AI-driven customization, in which algorithms analyze patient data to determine the design and composition of the printed graft; and accelerated regeneration of skin and other tissues to shorten healing time and reduce infection risk. The company states its platform has received approvals from the U.S. FDA, CE-MDR certification (2023) and designation by Korea's Ministry of Health and Welfare as an innovative medical technology for 3D printing-based diabetic foot treatment. Products are described as available in 18 countries. The company was founded by You Seokhwan, who serves as Founder and CEO.
Founding story
The company was founded in 2012 by You Seokhwan, who continues to serve as Founder and CEO.
Business model
The company commercializes bioprinting-based regenerative medicine products and treatment platforms for chronic disease, distributing them internationally following regulatory clearances in multiple jurisdictions.
Revenue is derived from commercialization of its regenerative medicine products and organ regeneration platform in the 18 countries where they are available.
Traction
The company reports CE MDR certification obtained in 2023, U.S. FDA registration of its Dr. Invivo medical device kit, Korean innovative medical technology designation for 3D printing-based diabetic foot treatment, and commercial availability in 18 countries. Clinical milestones cited include IEC approval for diabetic foot trials in India (August 2019), domestic IRB approval for diabetic foot treatment clinical trials (April 2020), and selection and publication of a diabetic foot clinical results abstract by the American Diabetes Association (June 2020). It has also won multiple technology awards, including the Innovation Technology Showcase Award at GSMA M360 APAC 2023 and a first-place presentation award at the 2019 AAPS conference.
Latest developments
In a financing reported by Korea Biomedical Review, ROKIT Healthcare raised 62.5 billion won (about $42.5 million) from global and domestic institutional investors through redeemable convertible preferred shares carrying a one-year lock-up. Foreign investors accounted for roughly 72 percent, or 45 billion won, of the total. Proceeds were designated primarily for research and development and clinical trials supporting global expansion of its AI-based regenerative medicine and organ rehabilitation technologies.
▸Full profile — market position, technology, go-to-market, geography
Market position
The company positions itself as a regenerative medicine biotechnology company applying 3D bioprinting and autologous cell therapy to chronic disease. It has been named a 2021 Preliminary Unicorn Company by Korea's Ministry of SMEs and Startups and the Korea Technology Finance Corporation, a Global IP Star Company by the Seoul Business Agency, and one of the Top 50 Healthcare Companies at the 2019 IFAH International Healthcare Forum. Listed comparable companies include restor3d, Aspect Biosystems and Organovo.
The company differentiates on hyper-personalization: AI-optimized, patient-specific bioprinted grafts made with the patient's own cells, aimed at faster healing and integration compared with conventional chronic wound and tissue treatments, supported by regulatory clearances in the U.S., Europe and Korea.
Technology
The core technology is an AI hyper-personalized organ regeneration platform built on 3D bioprinting and the use of autologous stem cells and tissue. 3D bioprinters produce patient-specific tissue grafts, while AI algorithms analyze patient data to optimize graft design and composition so that the graft matches the individual's condition and integrates with surrounding tissue to accelerate skin and tissue regeneration. A related product, the Dr. Invivo medical device kit, was registered with the U.S. FDA in August (year as stated in company materials). The company also reports work on AI-based kidney function prediction and organ rehabilitation technologies.
Go-to-market
The company pursues regulatory clearances (FDA, CE-MDR, Korean Ministry of Health and Welfare) and builds clinical evidence through investigator-led trials, conference presentations and published clinical results, alongside R&BD activity including clinical research, global contracts and participation in international medical conferences to support commercialization.
Patients with chronic conditions — principally diabetic foot ulcers, chronic kidney disease and degenerative arthritis — treated through hospitals and clinicians; clinical partners have included Korea University Guro Hospital and diabetic foot specialists in India.
Geography
Headquartered in South Korea, with products stated to be available in 18 countries. Clinical and regulatory activity spans Korea (Ministry of Health and Welfare innovative medical technology notification, IRB approval in 2020), the United States (FDA registration, conference presentations) and India (IEC approval for diabetic foot clinical trials in 2019, participation in the National Burn Conference of India).
Compiled by commissioned research from 5 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 9
launches, deals, and filingsThe company raised 62.5 billion won ($42.5 million) via redeemable convertible preferred shares with a one-year lock-up. Weiss Asset Management invested 30 billion won, Oasis Management 7 billion won, Pacific Alliance Group 5 billion won and LMR Partners 3 billion won; domestic investors including NH Investment & Securities, Asam Asset Management, Andra Asset Management, GVA Asset Management and Milestone Asset Management contributed 17.5 billion won. Proceeds are earmarked for R&D and clinical trials.
$42.5M source ↗
Investment from DRADS Capital, a fund associated with Harvard University neuroscientist Professor Tanzi.
Approval obtained with Professor Han Seung-kyu, President of the Korean Diabetic Foot Society and Director of Korea University Guro Hospital.
Overseen by Dr. Rajesh Kesavan, member of the Indian Diabetic Foot Society.
Company materials cite registration in August.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 5
primary sources listed
- Overview – Organ Regeneration Platformorp.rokithealthcare.com · web
5 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does ROKIT Healthcare do?
- South Korean regenerative medicine company using AI and 3D bioprinting to make personalized autologous tissue grafts.
- Who are ROKIT Healthcare's investors?
- ROKIT Healthcare's investors include Ascendo Ventures.